Toms Pascual

List of Publications by Year in Descending Order

62 papers	1,220 citations	19 h-index	34 g-index
91 ext. papers	1,942 ext. citations	6 avg, IF	4.12 L-index

#	Paper	IF	Citations
62	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.. *Cancer Treatment Reviews*, **2022**, 104, 102352	14.4	0
61	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. *EBioMedicine*, **2022**, 75, 103801	8.8	3
60	Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study. *Cancer Research*, **2022**, 82, PD8-03-PD8-03	10.1	
59	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. *Cancer Treatment Reviews*, **2022**, 106, 102392	14.4	4
58	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. *Frontiers in Oncology*, **2021**, 11, 744112	5.3	2
57	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. *Npj Breast Cancer*, **2021**, 7, 145	7.8	0
56	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. *Npj Precision Oncology*, **2021**, 5, 23	9.8	5
55	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. *Breast Cancer Research*, **2021**, 23, 42	8.3	3
54	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. *Frontiers in Oncology* , **2021**, 11, 638482	5.3	5
53	Gene expression profiles of breast cancer metastasis according to organ site. *Molecular Oncology*, **2021**,	7.9	3
52	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. *Npj Breast Cancer*, **2021**, 7, 1	7.8	54
51	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. *Clinical Cancer Research*, **2021**, 27, 3116-3125	12.9	3
50	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. *Npj Breast Cancer*, **2021**, 7, 8	7.8	2
49	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. *EBioMedicine*, **2021**, 69, 103451	8.8	3
48	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. *Breast Cancer Research*, **2020**, 22, 45	8.3	55
47	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. *Future Oncology*, **2020**, 16, 1801-1813	3.6	4
46	Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). *European Journal of Cancer Care*, **2020**, 29, e13253	2.4	1

45	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2020**, 84, 101965	14.4	39
44	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. *Nature Communications*, **2020**, 11, 385	17.4	36
43	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 33-43	21.7	52
42	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. *Cancers*, **2020**, 12,	6.6	9
41	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *Lancet Oncology, The*, **2020**, 21, 1455-1464	21.7	20
40	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 6141-6148	12.9	2
39	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. *Clinical Cancer Research*, **2020**, 26, 5820-5829	12.9	17
38	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. *Journal of the National Cancer Institute*, **2020**, 112, 46-54	9.7	48
37	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. *Breast Cancer Research*, **2019**, 21, 108	8.3	11
36	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. *Frontiers in Oncology*, **2019**, 9, 303	5.3	3
35	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer **2019**, 7, 90		40
34	Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer **2019**,		10
33	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. *Journal of Clinical Oncology*, **2019**, 37, 571-571	2.2	4
32	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. *Journal of Clinical Oncology*, **2019**, 37, 575-575	2.2	1
31	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. *Annals of Oncology*, **2019**, 30, 921-926	10.3	38
30	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. *Oncologist*, **2019**, 24, 893-900	5.7	12
29	A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. *Oncologist*, **2019**, 24, e1024-e1033	5.7	8
28	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. *Oncologist*, **2019**, 24, 603-611	5.7	20

27	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. *Frontiers in Oncology*, **2019**, 9, 1178	5.3	4
26	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.. *JCO Precision Oncology*, **2019**, 3, 1-6	3.6	4
25	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. *BMC Medicine*, **2019**, 17, 8	11.4	15
24	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. *Annals of Oncology*, **2018**, 29, 170-177	10.3	45
23	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. *Cancer Treatment Reviews*, **2018**, 67, 63-70	14.4	45
22	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. *Annals of Oncology*, **2018**, 29, 2121-2128	10.3	41
21	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. *European Journal of Cancer*, **2018**, 92, S117-S118	7.5	3
20	Abstract P2-09-04: Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer **2018**,		2
19	Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer **2018**,		3
18	Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial **2018**,		4
17	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. *Journal of Clinical Oncology*, **2018**, 36, 1025-1025	2.2	2
16	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. *Cancer Research*, **2017**, 77, 3540-3550	10.1	213
15	Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies. *Annals of Oncology*, **2017**, 28, v603	10.3	4
14	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. *PLoS ONE*, **2017**, 12, e0180192	3.7	19
13	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. *Breast*, **2017**, 34 Suppl 1, S19-S26	3.6	35
12	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. *Oncotarget*, **2017**, 8, 21930-21937	3.3	10
11	Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. *Ecancermedicalscience*, **2016**, 10, 632	2.7	10
10	Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?. *Journal of Clinical Oncology*, **2016**, 34, 3226-7	2.2	2

9	Phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer for neurotoxicity characterization: An Oncosur Study Group study.. *Journal of Clinical Oncology*, **2015**, 33, 1029-1029	2.2	
8	Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin).. *Journal of Clinical Oncology*, **2015**, 33, e22042-e22042	2.2	
7	Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institucion experience.. *Journal of Clinical Oncology*, **2015**, 33, e11570-e11570	2.2	1
6	The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. *Breast*, **2014**, 23, 201-8	3.6	51
5	Long-term outcomes of cisplatin-based chemotherapy in patients with stage II-III germ cell tumors: Center 30-year experience of a single center.. *Journal of Clinical Oncology*, **2013**, 31, 338-338	2.2	
4	Estrogen receptor in HER2-positive early breast cancer: Two different diseases?. *Journal of Clinical Oncology*, **2012**, 30, 642-642	2.2	2
3	Retrospective analysis of 132 patients with stage I seminoma: Observation versus adjuvant radiation or chemotherapy in a single institution.. *Journal of Clinical Oncology*, **2012**, 30, e15033-e15033	2.2	
2	Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value. *Breast Cancer Research*, **2011**, 13,	8.3	78
1	Lobular carcinoma of the breast: outcome of 205 patients. *Breast Cancer Research*, **2011**, 13,	8.3	78